UK to address surgery cancellations
This article was originally published in Clinica
"There is no room for complacency." This is how the UK's Department of Health underlined its commitment to tackle surgery cancellations, in light of data released today. In England, during the period July-September (Q2 2006-07), 12,275 operations (0.8% of all elective surgery) were cancelled at the last minute for non-clinical reasons, a small improvement on the 13,058 of Q2 2005-06. Delays in re-arranging the operation, although significantly better than a year ago, remain a source of concern: 637 (5.2%) cases were not treated within 28 days; last year, the figure was 1,160 (8.9%). At the end of October 2006, the number of patients waiting in England over 13 weeks for an operation stood at 188,300, down 2.3% from September and 9.4% since October 2005. The NHS performs 662,000 more operations per year now than in 1997, the DoH notes.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.